As I See It: FDA and the First Amendment

Share this article:
James G. Dickinson
James G. Dickinson

FDA has long had an uneasy relationship with the First Amendment. Its authority to curb “misbranding” has been interpreted by the courts to also cover “labeling” in a variety of forms, including oral statements by sales reps.

Now the agency has gone further, alleging in a Warning Letter to Aegerion Pharmaceuticals that oral statements its CEO made on a TV program for investors misbranded its cholesterol drug Juxtapid by making reference to the drug's off-label uses.

This is a far cry from a sales rep's pitch to a prescriber about an unapproved use. In the Aegerion case, the CEO meant to impress potential investors, not sell Juxtapid for uses not approved by FDA.

In a recent blog post, the Washington Legal Foundation's Rich Samp said that FDA, after federal court rulings that restrict its regulation of truthful speech about approved drugs, “shows little or no respect for those rulings and apparently believes it is not bound by the First Amendment.”

Indeed, FDA's Warning Letter to Aegerion is a bureaucratic thumb in the eye to the US Court of Appeals for the Second Circuit, which barely a year ago threw out an FDA lower court win against a salesman in US v. Caronia verbally promoting an off-label use of a drug to a doctor.

FDA's behavior is supported by many, including the Harvard Law Review, who see it as a necessary counter to drug companies who would promote new uses for approved drugs, and expand sales accordingly, without doing the clinical studies the law requires.

Fair enough, says Samp. But when FDA criminalizes speech regardless of intent, as in the Aegerion and Caronia cases, a line needs to be drawn in the sand.


James G. Dickinson is editor of Dickinson's FDA Webview (fdaweb.com).

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in As I See It

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications